New Member Mini-Bios
Kristina Adams Waldorf, MD
Kristina Adams Waldorf, MD
Professor, Obstetrics & Gynecology and Global Health
UW Medicine, Seattle, WA USA [READ MORE]
Articles by joefner@cytokinesociety.org
New Member Mini-Bios
De’Broski R. Herbert, PhD
De’Broski R. Herbert PhD
Associate Professor of Immunology
University of Pennsylvania, PennVet
Philadelphia, PA USA [READ MORE]
New Member Mini-Bios
Rebecca Porritt, PhD
Rebecca Porritt, PhD
Research Scientist I, Department of Pediatrics and Biomedical Sciences
Assistant Professor of Pediatrics, UCLA School of Medicine
Cedars-Sinai Medical Center, Los Angeles, CA, USA [READ MORE]
New Member Mini-Bios
Moshe Arditi, M.D.
Moshe Arditi, M.D.
Executive Vice-Chair, Department of Pediatrics for Research
Professor of Pediatrics, Cedars Sinai Medical Center and UCLA School of Medicine
Director, Division of Pediatric Infectious Diseases and Immunology,
Director, Infectious and Immunologic Diseases Research Center (IIDRC), Department of Biomedical Science, Cedars Sinai Medical Center, Los Angeles, CA, USA [READ MORE]
Reviews of Interest
REVIEWS OF INTEREST
Reviews of Interest to cytokine biologists. [READ MORE]
Reviews of Interest
COVID-19 special collection
Reviews of interest related to COVID-19 and cytokine biology [READ MORE]
Clinical Trials
Cytokine Clinical Trials
By Marta Catalfamo Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (DiTuSarc) ClinicalTrials.gov Identifier: NCT05080790 Contact: Daniel Pink, Dr. 033631 73527 daniel.pink@helios-gesundheit.de Contact: Melanie Prause 069 7601 4211 prause.melanie@ikf-khnw.de Sponsors and Collaborators Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest EUSA Pharma, Inc. [READ MORE]
News
Trials of Interferon Lambda for SARS-CoV-2 /COVID-19: A Status Report
Early in the COVID-19 pandemic, several groups of scientists proposed IFN- as a potential therapy for SARS-CoV-2 infection (O’Brien et al., Clinical Infectious Diseases, 2020; Prokunina-Olsson et al., Journal of Experimental Medicine, 2020). That suggestion was based on evidence that the IFN- family provides important first-line immunological defense against viral respiratory tract infections and data indicating that SARS-CoV-2 induces weak expression of IFNs. There are no licensed IFN- therapeutics, however, pegylated-interferon lambda 1, which was shown to be safe and effective in testing among >3,000 patients with chronic viral hepatitis infections, is available as an investigational agent through Eiger Biopharmaceuticals. Several phase 2 clinical trials have been launched to assess the safety and efficacy of pegylated-IFN-1 for treatment or prevention of SARS-CoV-2 / COVID-19. Findings from two trials are now available. [READ MORE]
Society News
ICIS 2021 Leadership Election Results
Please click on the images for Mini-Bios: Officers – 2 year terms Sarah L. Gaffen, PhD, President-Elect (2021 – 2023) Dusan Bogunovic, PhD, Treasurer (2021-2023) Council Members – 3 year terms Judith E Allen, FRSE, FRSB, FMedSci, Council (2022-2024) You-Me Kim, PhD, Council (2022 – 2024) Nominations Committee – 3 [READ MORE]
Young Investigators to Watch...2022 Winners
2020 Milstein Young Investigator Award Winners:
Every year three-five awards are granted to individuals who have made notable contributions to either basic or clinical research. This award is provided by a generous gift of the Milstein Family and all ICIS members who will attend the upcoming annual conference and who have received a Ph.D or M.D. within the previous 10 years are eligible, but may be extended by 1 year due to parental leave. [READ MORE]